OXATOMIDE MONOHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H30N4O.H2O
Molecular Weight	444.5686
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O=C1NC2=CC=CC=C2N1CCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=WUVRHFANMRXNRX-UHFFFAOYSA-N

InChI=1S/C27H30N4O.H2O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23;/h1-8,10-15,26H,9,16-21H2,(H,28,32);1H2

HIDE SMILES / InChI

Molecular Formula	C27H30N4O
Molecular Weight	426.5533
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24474428
Curator's Comment: description was created based on several sources, including, http://www.hindawi.com/journals/jphar/2013/629593/

Oxatomide is a H1-histamine receptor antagonist developed for the treatment of broad spectrum of allergic and other hypersensitivity reactions. The drug is currently marketed in Japan, Taiwan, Italy, Portugal, Indonesia, Argentina, South Africa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/8753840	Antagonist 2778		6.23 null [pIC50]

Conditions

Condition	Modality	Highest Phase	Product
Chronic urticaria 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7014277	Primary	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014
Follicular conjunctivitis 2 Sources: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_025293_RCP.pdf&retry=0&sys=m0b1l3	Primary	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014
Asthma 241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12804426	Palliative	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014
Perennial allergic rhinitis 47 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1982723	Primary	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014
Atopic eczema 2 Sources: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_025293_RCP.pdf&retry=0&sys=m0b1l3	Primary	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014
Food allergy 2 Sources: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_025293_RCP.pdf&retry=0&sys=m0b1l3	Primary	Approved 8429	TINSET Approved Use Prevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date 2014

PubMed

Title	Date	PubMed
Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects.	1995 Feb	7655991
Pharmacokinetics of oxatomide in preterm infants.	2002	12635496
High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma.	2002	12442638
The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.	2002 Dec	12487225
Pranlukast: a review of its use in the management of asthma.	2003	12699401
Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules.	2003 Oct	14530792
West syndrome associated with administration of a histamine H1 antagonist, oxatomide.	2004	15682834
Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants.	2005 Feb	15684493
[Comparison of clinical efficacy and cost-quality of antihistamines in early treatment for Japanese cedar pollinosis].	2006 May	16883093
Effect of inhibitor of tumor necrosis factor-alpha and oxatomide on immune mediated otitis media.	2006 Sep	16954996
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

Oxatomide should be taken twice daily, after breakfast and after dinner: 30 mg for adults and 0.5 mg/kg for children older tan 1 year.

Route of Administration: Oral

In Vitro Use Guide

The effect of oxatomide on the immunologic release of preformed (histamine and tryptase) and de novo synthesized mediators (leukotriene C4:LTC4 and prostaglandin D2:PGD2) from human basophils and mast cells purified (from 10 to 82%) from human lung parenchyma (HLMC) and skin tissue (HSMC) was studied in vitro. Preincubation (15 min, 37 degrees C) of basophils with oxatomide (10(-7)-10(-5) M) before Der p I antigen or anti-IgE challenge concentration-dependently (10-40%) inhibited the immunologic release of histamine and LTC4. Oxatomide (10(-7)-10(-5) M) also inhibited (10-40%) histamine, tryptase and LTC4 release from HLMC activated by anti-IgE. In addition, oxatomide caused a concentration-dependent inhibition of histamine, tryptase and PGD2 release from HSMC immunologically challenged with a monoclonal antibody against the alpha chain of the high affinity receptor for IgE (anti-Fc epsilon RI) or anti-IgE.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:09:07 GMT 2023` Edited by `admin` on `Sat Dec 16 10:09:07 GMT 2023`
Record UNII	AH84KRJ5KM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXATOMIDE MONOHYDRATE

Common Name

English

2H-BENZIMIDAZOL-2-ONE, 1-(3-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)PROPYL)-1,3-DIHYDRO-, HYDRATE (1:1)

Systematic Name

English

2H-BENZIMIDAZOL-2-ONE, 1-(3-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)PROPYL)-1,3-DIHYDRO-, MONOHYDRATE

Systematic Name

English

Code System Code Type Description

SMS_ID

100000130699